Plavix

— THERAPEUTIC CATEGORIES —
  • Thromboembolic disorders
PAGE CONTENTS
  • Jump to Section
  • Generic Name & Formulations
  • Indications
  • Dosage and Administration
  • Contraindications
  • Boxed Warnings
  • Warnings/Precautions
  • Pharmacokinetics
  • Interactions
  • Adverse Reactions
  • Clinical Trials
  • Note
  • Patient Counseling

    • Plavix Generic Name & Formulations

    Legal Class

    Rx

    General Description

    Clopidogrel (as bisulfate) 75mg, 300mg; tabs.

    Pharmacological Class

    P2Y12 platelet inhibitor (thienopyridine).

    How Supplied

    Tabs 75mg—90; 300mg—30

    Manufacturer

    BMS/Sanofi Pharmaceuticals Partnership

    Generic Availability

    YES

    Plavix Indications

    Indications

    To reduce the rate of MI and stroke in patients with: non-ST-segment elevation acute coronary syndrome (unstable angina/non-ST-elevation MI) or acute ST-elevation MI; history of recent MI, recent stroke, or established peripheral arterial disease; see full labeling.

    Plavix Dosage and Administration

    Adult

    Acute coronary syndrome (give with aspirin): initially give one 300mg loading dose, then continue at 75mg once daily. Recent MI, recent stroke, or established peripheral arterial disease: 75mg once daily without a loading dose.

    Children

    Not established.

    Plavix Contraindications

    Contraindications

    Active pathologic bleeding (eg, peptic ulcer, intracranial hemorrhage).

    Plavix Boxed Warnings

    Boxed Warning

    Diminished antiplatelet effect in patients with two loss-of-function alleles of the CYP2C19 gene.

    Plavix Warnings/Precautions

    Warnings/Precautions

    CYP2C19 poor metabolizers: diminished effectiveness in those who are homozygous for nonfunctional alleles of the CYP2C19 gene. Perform testing for the CYP2C19 genotype before starting therapy; consider alternative treatment if identified. Increased risk of bleeding. Premature discontinuation increases risk of cardiovascular events; if temporarily discontinued (eg, to treat bleeding or surgery; if possible, interrupt therapy for 5 days before such surgery); restart as soon as possible. Moderate and severe renal impairment. Pregnancy. Labor & delivery: discontinue 5–7 days prior to labor, delivery, or neuraxial blockade. Nursing mothers.

    Plavix Pharmacokinetics

    See Literature

    Plavix Interactions

    Interactions

    Avoid concomitant CYP2C19 inhibitors (eg, omeprazole, esomeprazole) or strong CYP2C19 inducers (eg, rifampin). Antagonized by opioid agonists (eg, morphine, others); consider using IV anti-platelet agent instead. Caution with concomitant other drugs that increase risk of bleeding (eg, NSAIDs, warfarin, SSRIs, SNRIs, other antiplatelet agents); evaluate for blood loss if concomitant with other antiplatelets. Avoid concomitant repaglinide; if unavoidable, initiate repaglinide at 0.5mg before each meal; max 4mg/day; monitor glucose frequently.

    Plavix Adverse Reactions

    Adverse Reactions

    Bleeding (may be fatal), epistaxis, hematuria, bruising, ulcers, rash; hypersensitivity reactions, thrombotic thrombocytopenic purpura.

    Plavix Clinical Trials

    See Literature

    Plavix Note

    Not Applicable

    Plavix Patient Counseling

    See Literature

    Images

    • Latest News Your top articles for Wednesday

    • Haymarket Medical NetworkTop Picks

    • Loading...

      Continuing Medical Education (CME/CE) Courses

      Show More